Literature DB >> 2200496

Immunohistochemical and immunocytochemical study of bladder carcinomas using the epithelium-specific, tumour-associated monoclonal antibodies HMFG1 and AUA1.

E Anagnostaki1, D Skarlos, N Tamvakis, P Psaropoulou, E Blana, A Bamias, S Legaki, G Aravantinos, C Deliveliotis, K Dimopoulos.   

Abstract

The antigenic expression of normal bladder epithelium and transitional carcinomas has been studied using the epithelium-specific, tumour-associated monoclonal antibodies HMFG1 and AUA1. Tissues from 79 cases of bladder carcinoma and 11 cases of non-neoplastic bladder tissues were stained with both the haematoxylin-eosin (H/E) and the indirect two-stage immunoperoxidase methods using the monoclonal antibodies (MAbs) HMFG1 and AUA1 at a concentration of 25 micrograms ml-1. Positive and negative controls were also used. Moreover, 46 urine smears prepared after cytocentrifugation were stained with both the Papanicolaou and the indirect two-stage immunoperoxidase methods. The results showed that HMFG1 reacted with the majority of cases of grade III carcinomas and carcinomas in situ and with a subset only of low-grade (I and II) carcinomas. The pattern of staining showed the following characteristics: (1) the epithelial surface membrane stained both in normal bladder and bladder carcinomas (surface of the papillae), (2) a variant number of cancer cells, increasing with the degree of malignancy, showed membrane and/or cytoplasmic staining, (3) tumours of the same histological grade showed antigenic heterogeneity. The MAb AUA1 was not widely expressed. The immunocytochemical study confirmed the reaction of HMFG1 with a variant number of malignant urothelial cells exfoliated in urine. Their reaction with AUA1 was much more limited. The immunocytochemical staining seemed to be more sensitive in the detection of malignant cells in some cases which had been characterized as negative or suspicious for malignancy by the Papanicolaou examination. The intravesical treatment with chemotherapeutic agents did not seem to influence the antigenic expression of malignant urothelial cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2200496      PMCID: PMC2149508     

Source DB:  PubMed          Journal:  Br J Cancer Suppl        ISSN: 0306-9443


  34 in total

1.  Biochemical and immunologic diagnosis of cancer. Urinary immunocytology and bladder carcinomas.

Authors:  R Arndt; H Huland
Journal:  Tumour Biol       Date:  1987

2.  Antigenic deletion and prognosis of patients with stage A transitional cell bladder carcinoma.

Authors:  J M Decenzo; P Howard; C E Irish
Journal:  J Urol       Date:  1975-12       Impact factor: 7.450

3.  Production and characterization of mouse monoclonal antibodies to human bladder tumor-associated antigens.

Authors:  D A Young; G R Prout; C W Lin
Journal:  Cancer Res       Date:  1985-09       Impact factor: 12.701

4.  Monoclonal antibodies against transitional cell carcinoma for detection of malignant urothelial cells in bladder washing.

Authors:  D K Chopin; J B deKernion; D L Rosenthal; J L Fahey
Journal:  J Urol       Date:  1985-08       Impact factor: 7.450

5.  The prognostic value of cell surface antigens in low grade, non-invasive, transitional cell carcinoma of the bladder.

Authors:  A K Young; E Hammond; A W Middleton
Journal:  J Urol       Date:  1979-10       Impact factor: 7.450

6.  Correlation of the cell surface antigens with stage and grade in cancer of the bladder.

Authors:  R C Emmott; N Javadpour; S M Bergman; T Soares
Journal:  J Urol       Date:  1979-01       Impact factor: 7.450

7.  Effect of intravesical Bacillus Calmette-Guérin on detection of a urothelial differentiation antigen in exfoliated cells of carcinoma in situ of the human urinary bladder.

Authors:  J L Huffman; Y Fradet; C Cordon-Cardo; H W Herr; C M Pinsky; H F Oettgen; L J Old; W F Whitmore; M R Melamed
Journal:  Cancer Res       Date:  1985-10       Impact factor: 12.701

8.  Expression of Ca antigen on human urinary bladder tumors.

Authors:  B Czerniak; L G Koss
Journal:  Cancer       Date:  1985-05-15       Impact factor: 6.860

9.  Murine hybridoma antibodies against human transitional carcinoma-associated antigens.

Authors:  E M Messing; J E Bubbers; K E Whitmore; J B deKernion; M S Nestor; J L Fahey
Journal:  J Urol       Date:  1984-07       Impact factor: 7.450

10.  Epithelial markers in prostatic, bladder, and colorectal cancer: an immunoperoxidase study of epithelial membrane antigen, carcinoembryonic antigen, and prostatic acid phosphatase.

Authors:  E Heyderman; B M Brown; T C Richardson
Journal:  J Clin Pathol       Date:  1984-12       Impact factor: 3.411

View more
  4 in total

1.  Immunoscintigraphy with iodine-131-labelled monoclonal antibody AUA1 in patients with transitional cell carcinoma of the bladder.

Authors:  J Zorzos; D V Skarlos; P Pozatzidou; A Zizi; A Bakiras; S Koritsiadis; D Pectasidis; P Koutsioumba; A A Epenetos; M Likourinas
Journal:  Urol Res       Date:  1994

2.  A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients.

Authors:  Mark Kowalski; Joycelyn Entwistle; Jeannick Cizeau; Demi Niforos; Shauna Loewen; Wendy Chapman; Glen C MacDonald
Journal:  Drug Des Devel Ther       Date:  2010-11-15       Impact factor: 4.162

3.  Intravesical administration of tumor-associated monoclonal antibody AUA1 in transitional cell carcinoma of the bladder: a study of biodistribution.

Authors:  J Zorzos; D V Skarlos; A A Epenetos; D Pectasides; P Koutsioumba; J Elemenoglou; A Bakiras; M Likourinas; K Dimopoulos
Journal:  Urol Res       Date:  1993

4.  Immunolocalization of transitional cell carcinoma of the bladder with intravesically administered technetium-99m labelled HMFG1 monoclonal antibody.

Authors:  J Malamitsi; J Zorzos; A D Varvarigou; S Archimandritis; C Dassiou; D V Skarlos; P Dimitriou; M Likourinas; A Zizi; C Proukakis
Journal:  Eur J Nucl Med       Date:  1995-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.